<DOC>
	<DOCNO>NCT02187250</DOCNO>
	<brief_summary>The purpose study determine whether monotherapy treatment phosphodiesterase-4 ( PDE-4 ) inhibitor roflumilast effective treatment glucagon-like protein 1 ( GLP-1 ) liraglutide treatment metformin monotherapy treatment obese woman polycystic ovary syndrome ( PCOS ) regard weight reduction treat . The investigator anticipate great change body weight patient roflumilast treatment liraglutide metformin .</brief_summary>
	<brief_title>PDE-4 Inhibitor Roflumilast GLP-1 Agonist Liraglutide Polycystic Ovary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Phosphodiesterase 4 Inhibitors</mesh_term>
	<criteria>18 year old menopause polycystic ovary syndrome ( NICHD criterion ) BMI 30 kg/mÂ² high depression type 1 type 2 diabetes mellitus history carcinoma history pancreatitis Cushing 's syndrome congenital ( nonclassic ) adrenal hyperplasia significant cardiovascular , kidney hepatic disease use medication metformin know suspected affect reproductive metabolic function use statin , within 90 day prior study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>PCOS</keyword>
	<keyword>PDE-4 inhibitor</keyword>
	<keyword>roflumilast</keyword>
	<keyword>liraglutide</keyword>
	<keyword>metformin</keyword>
	<keyword>obesity</keyword>
</DOC>